PSMO-05 - HIV treatment: The future of preventative care and management

Meeting room 2.60
Organised by The FIP Special Interest Group on New Medicines in collaboration with the FIP Community Pharmacy Section

Chair(s)

Prof. Takuya Kumamoto, ExCo Member FIP New Medicines Special Interest Group, Japan

Introduction

Approximately 38 million people worldwide are living with HIV, with 75% receiving antiretroviral treatment. New HIV infections have fallen by 40% since the peak in 1988. The World Health Organization aims to reduce infections from 1.5 million in 2020 to 335,000 in 2030, and deaths from 680,000 to 240,000 in the 2022-2030 Global Health Sector Strategy on HIV. Pharmacological strategies of pre- and post-exposure prophylaxis are being implemented to effectively prevent transmission. Pharmacists’ expertise and accessibility can be leveraged for various roles in HIV prevention and screening, including point-of-care testing and self-testing. In addition, anti-HIV medicines that affect the life cycle of the virus, such as reverse transcriptase and protease inhibitors, have been discovered and developed. The discovery of long-acting injectable integrase inhibitors has made it possible to maintain activity for two months, offering good adherence and reducing the stigma of daily intake. In this session, we will discuss the role of pharmacists in HIV prevention and management and review recent developments in drug discovery research for anti-HIV medicines.

Programme

 

11:00 – 11:05

Introduction by the chair
Prof. Takuya Kumamoto, ExCo Member FIP New Medicines Special Interest Group, Japan
11:05 – 11:20

Short presentation from selected oral abstract
11:20 – 11:50 New horizon of drug discovery for anti-HIV medicines
Prof. Hirokazu Tamamura, Tokyo Medical and Dental University, Japan
11:50 – 12:20 Role of community pharmacists in the prevention, screening and management of HIV
Dr Sham Moodley, ExCo member of the FIP Community Pharmacy Section, South Africa
12:20 – 12:30  Final questions and closing

Learning objectives

  • To understand the role of pharmacists in HIV prevention, screening, and management.
  • To identify strategies and developments in anti-HIV medicine discovery that affect the life cycle of the virus.
  • To identify how the science and practice of HIV treatment have been developed collaboratively.

Summary

  • Anti-HIV medicines have been mainly developed based on the reverse transcriptase and protein inhibitors. Recent developments in integrated inhibitors enable long-acting medicines and prevention.
  • FIP toolkit supports pharmacists in HIV prevention, screening, and management.